Find reports of previous years, results presentations and webcasts in our Download Center
Annual Report 2022
On the move since 150 years: Siegfried significantly increases sales and profits in 2022
Siegfried CEO Wolfgang Wienand in conversation
Key Figures 2022
of Sales and Profits
Net sales (in million CHF)
Net sales in 2022 reached CHF 1229.5 million.
Core EBITDA (in million CHF)
Core EBITDA in 2022 reached CHF 272.5 million.
Core net profit (in million CHF)
Core net profit in 2022 amounts to CHF 127.8 million.
The number of employees reached 3564 FTEs.
Letter to the Shareholders
2022 was another year of strong profitable growth for the Siegfried Group. In a once more challenging environment, the company demonstrated its resilience and delivered another record result. Sales growth remained strong and profitability raised to a new level.
The Year 2022
Two new board members
Dr. Alexandra Brand and Dr. Beat Walti were elected in April to the Board of Directors of Siegfried Holding AG.
New production plant in Minden, Germany
The construction of a new large-scale production plant of CHF 100 million investments has begun. The plant will be equipped with state-of-the-art technology and highly sustainable standards.
Integration of two new Spanish sites
Barberà del Valles and El Masnou, located in the Barcelona region, have been successfully integrated into the Siegfried landscape.
Support vaccine filling for Novovax
Novavax and Siegfried extended their collaboration for the commercial filling of Novavax’s protein-based Coronavirus vaccine at Siegfried’s manufacturing site in Hameln, Germany.
Dow Jones Sustainability Index Europe
Siegfried was confirmed in the Dow Jones Sustainability Index Europe (DJSI) for the second consecutive year. Our company is the only Contract Development and Manufacturing Organization in DJSI Europe.